*.- Sin embargo, se observó una mediana de beneficio de SG de aproximadamente 2,5 meses con el régimen de 3 fármacos frente a la quimioterapia sola, lo que se traduce en un cociente de riesgos instantáneos de 0,75.
*.- También se encontró que los regímenes tienen perfiles de seguridad favorables, según Goldman.
*.- La adición de inmunoterapia a la columna vertebral de la quimioterapia no tuvo el costo de una toxicidad significativa.
RESULTS :
Compared with EP, DEP was projected to increase life expectancy by 0.86 LYs (1.73 vs. 0.87) and 0.44 QALYs (0.93 vs. 0.49). The incremental treatment cost was $95,907, and the corresponding ICER was $216,953/QALY. The result was most sensitive to variation of durvalumab acquisition cost. Probabilistic sensitivity analysis revealed that the probability of DEP over EP regimen to be cost-effective was 9.4% at a willingness-to-pay threshold of $150,000/QALY. In the case of reducing the price of durvalumab by 30.7%, DEP was more cost-effective than EP.
CONCLUSION:
From the perspective of the US payer, adding durvalumab to EP is estimated to be not cost-effective compared with EP alone for untreated ES-SCLC patients . ...